Work

Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory Waldenstrom Macroglobulinemia

Year: 2014

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v124.21.3081.3081

Authors: Irene M. Ghobrial, Robert Allyn Redd, Jeffrey Matous, Philippe Armand, Erica N Boswell, Stacey Chuma, Kimberly Noonan, Megan H. MacNabb, Ranjit Banwait, Courtney Hanlon, Houry Leblebjian, Diane Warren, Jorge J. Castillo, Jacob P. Laubach, Claudia E. Paba-Prada, Kenneth C. Anderson, Paul G. Richardson, Edie A. Weller, Steven P Treon

Institutions: Harvard University, Dana-Farber Cancer Institute, Rocky Mountain Cancer Centers, Dana-Farber/Harvard Cancer Center

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2979401570

FWCI: 0.3

Cites:

Cited by: 4

Related to: 10